Checkpoint Therapeutics Merger Awaits Stockholder Vote

An announcement from Checkpoint Therapeutics ( (CKPT) ) is now available.

On March 9, 2025, Checkpoint Therapeutics entered into a Merger Agreement with Sun Pharmaceutical Industries, planning a merger with Snoopy Merger Sub, a subsidiary of Sun Pharma. The merger is subject to customary conditions, including the expiration of the HSR waiting period, which concluded on May 21, 2025. The merger is expected to close around May 30, 2025, following a stockholder vote on May 28, 2025. Additionally, a class action lawsuit against Checkpoint and its CEO was dismissed on May 19, 2025, with the court ruling in favor of the company. The lead plaintiff has 30 days to appeal the decision.

The most recent analyst rating on (CKPT) stock is a Hold with a $4.10 price target. To see the full list of analyst forecasts on Checkpoint Therapeutics stock, see the CKPT Stock Forecast page.

Spark’s Take on CKPT Stock

According to Spark, TipRanks’ AI Analyst, CKPT is a Neutral.

Checkpoint Therapeutics faces significant financial challenges with declining revenues and negative margins. However, the technical analysis shows strong upward momentum, and the recent merger agreement with Sun Pharma provides a positive outlook. The valuation remains unattractive due to the negative P/E ratio. Overall, while there are short-term opportunities, substantial financial issues pose long-term risks.

To see Spark’s full report on CKPT stock, click here.

More about Checkpoint Therapeutics

Checkpoint Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on developing and commercializing novel treatments for cancer. The company is involved in creating therapies that target specific cancer pathways, aiming to improve patient outcomes in oncology.

Average Trading Volume: 2,670,233

Technical Sentiment Signal: Buy

Current Market Cap: $362M

See more data about CKPT stock on TipRanks’ Stock Analysis page.